NRx Pharmaceuticals’ (NRXP) Buy Rating Reiterated at BTIG Research

BTIG Research reaffirmed their buy rating on shares of NRx Pharmaceuticals (NASDAQ:NRXP) in a report published on Tuesday,Benzinga reports. The firm currently has a $10.00 price target on the stock.

Other equities analysts also recently issued reports about the company. Wall Street Zen downgraded NRx Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. HC Wainwright reissued a “buy” rating on shares of NRx Pharmaceuticals in a research report on Monday, August 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research note on Wednesday, August 5th. Ascendiant Capital Markets raised their price objective on shares of NRx Pharmaceuticals from $48.00 to $49.00 and gave the company a “buy” rating in a research note on Monday, April 27th. Finally, D. Boral Capital restated a “buy” rating and issued a $34.00 price objective on shares of NRx Pharmaceuticals in a report on Tuesday, May 5th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.50.

NRx Pharmaceuticals Stock Up 5.4%

NRXP opened at $3.51 on Tuesday. NRx Pharmaceuticals has a 52 week low of $1.62 and a 52 week high of $5.05. The business has a fifty day simple moving average of $3.76 and a 200-day simple moving average of $3.00. The firm has a market cap of $151.98 million, a P/E ratio of -6.38 and a beta of 2.18.

NRx Pharmaceuticals (NASDAQ:NRXP) last posted its quarterly earnings data on Monday, August 17th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.33). The company had revenue of $1.10 million during the quarter, compared to analysts’ expectations of $1.33 million. Sell-side analysts expect that NRx Pharmaceuticals will post -0.3 earnings per share for the current year.

Institutional Investors Weigh In On NRx Pharmaceuticals

Several institutional investors have recently modified their holdings of NRXP. Ethos Financial Group LLC grew its stake in shares of NRx Pharmaceuticals by 33.6% during the first quarter. Ethos Financial Group LLC now owns 15,900 shares of the company’s stock worth $34,000 after purchasing an additional 4,000 shares in the last quarter. AdvisorShares Investments LLC raised its stake in NRx Pharmaceuticals by 28.2% in the first quarter. AdvisorShares Investments LLC now owns 420,467 shares of the company’s stock valued at $896,000 after buying an additional 92,463 shares in the last quarter. Anson Funds Management LP raised its stake in NRx Pharmaceuticals by 50.3% in the fourth quarter. Anson Funds Management LP now owns 3,043,957 shares of the company’s stock valued at $8,249,000 after buying an additional 1,018,853 shares in the last quarter. State Street Corp lifted its holdings in NRx Pharmaceuticals by 14.0% during the 4th quarter. State Street Corp now owns 86,984 shares of the company’s stock worth $236,000 after buying an additional 10,700 shares during the last quarter. Finally, Commonwealth Equity Services LLC purchased a new stake in NRx Pharmaceuticals during the 4th quarter worth about $994,000. 4.27% of the stock is owned by hedge funds and other institutional investors.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.